22:33 , Mar 27, 2019 |  BC Innovations  |  Translation in Brief

A mitochondrial shield from cell death

An IBM-Mount Sinai team has challenged the prevailing idea that high mitochondrial counts in tumor cells enhance cancer’s sensitivity to apoptosis-inducing therapies by showing that low numbers of the organelle actually do the trick. The...
01:35 , Aug 11, 2017 |  BC Innovations  |  Tools & Techniques

K follows C in chemoproteomics

A year after publishing a map of druggable cysteines in the proteome, Ben Cravatt’s lab at Scripps has reported its chemoproteomics tools can also profile lysines. By identifying reactive lysines in dozens of proteins for...
01:17 , Nov 11, 2016 |  BC Innovations  |  Tools & Techniques

Chemistry beyond candidates

Six years after ramping up its focus on research chemistry, AstraZeneca plc is showcasing the fruits in three areas central to innovative compound creation: new paradigms for covalent target modification, algorithms for predicting macrocycle cell...
08:00 , Jan 16, 2014 |  BC Innovations  |  Targets & Mechanisms

Putting a lid on cancer cell proteasomes

Blocking the catalytic activity of proteasomes is a tried-and-true strategy in multiple myeloma, but use of marketed inhibitors is limited by drug resistance and lack of efficacy in solid tumors. Now, a team from The...
08:00 , Feb 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1; BAK); B cell lymphoma 2 (BCL-2; BCL2); BCL2 homology domain 3 (BH3) Structural studies have identified regions...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1; BAK); B cell lymphoma 2 (BCL-2; BCL2); BCL3 homology domain 3 (BH3) Structural studies have identified regions...
07:00 , Mar 17, 2011 |  BC Innovations  |  Targets & Mechanisms

MCL1's resistance story

Separate studies by Harvard Medical School and Roche 's Genentech Inc. unit have shown that increased levels of myeloid leukemia cell differentiation protein, an antiapoptotic protein in the B cell lymphoma 2 family, can enable...
07:00 , Sep 30, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1) A study in mice suggests that inhibiting the mitochondrial apoptotic pathway could help treat...
07:00 , Oct 30, 2008 |  BC Innovations  |  Cover Story

BCL-2 double take

Researchers at the Burnham Institute for Medical Research and the Dana-Farber Cancer Institute have independently identified peptides that modulate mitochondrial apoptosis and may have promise in cancer. The therapeutic strategies are, however, quite different: in...